Peter Powchik, SVP Clinical Development & Reg at REGENERON PHARMACEUTICALS INC (REGN), sold 48,000 shares at $276.75 ($13.2M) on 2014-01-02, disclosed to the SEC on 2014-01-03.
Scheduled sale ($13.2M) by SVP Clinical Development & Reg under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $276.09 | 5,325 | $1.5M | 11.1% |
| 2 | $276.09 | 22,007 | $6.1M | 45.9% |
| 3 | $272.88 | 3,000 | $819K | 6.2% |
| 4 | $273.77 | 5,602 | $1.5M | 11.6% |
| 5 | $274.69 | 3,777 | $1.0M | 7.8% |
| 6 | $276.04 | 6,893 |
| $1.9M |
| 14.4% |
| 7 | $276.75 | 1,296 | $359K | 2.7% |
| 8 | $277.50 | 100 | $28K | 0.2% |
| Total | $275.52 avg | 48,000 | $13.2M | 100% |
| Filing → |
| REGN | SELL | 2013-12-20 | $2.5M | — | Filing → |
| REGN | SELL | 2013-12-17 | $2K | — | Filing → |
| REGN | SELL | 2013-01-04 | $2.5M | — | Filing → |